trial
as of 2026-07-01Pharmacological Modulation of Hippocampal Activity in Psychosis 2
NCTId NCT04559529
at a glance
Phase 2 · Completed
Enrollment 62 (actual)
Sponsored by Vanderbilt University Medical Center
Primary completion 2023-12-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
62 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2020-09-23
Primary completion
2023-12-31
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Vanderbilt University Medical CenterLead Sponsor
Investigators
1
Stephan Heckers, MDPrincipal Investigator
Sites
1 total
Nashville, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
62
Phase
PHASE2
Primary Completion Date
2023-12-31
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
investigator
person